[1]王圣杰,刘俊中,尹帅领,等.颅内动脉粥样硬化性狭窄Enterprise支架置入术后支架内再狭窄的危险因素分析[J].中国临床神经外科杂志,2023,28(01):5-7,56.[doi:10.13798/j.issn.1009-153X.2023.01.002]
 WANG Sheng-jie,LIU Jun-zhong,YIN Shuai-ling,et al.Risk factors for in-stent restenosis in patients with intracranial atherosclerotic stenosis after Enterprise stenting[J].,2023,28(01):5-7,56.[doi:10.13798/j.issn.1009-153X.2023.01.002]
点击复制

颅内动脉粥样硬化性狭窄Enterprise支架置入术后支架内再狭窄的危险因素分析()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
28
期数:
2023年01期
页码:
5-7,56
栏目:
论著
出版日期:
2023-01-25

文章信息/Info

Title:
Risk factors for in-stent restenosis in patients with intracranial atherosclerotic stenosis after Enterprise stenting
文章编号:
1009-153X(2023)01-0005-03
作者:
王圣杰刘俊中尹帅领郭广涛毛立武周游孟飞龙谢晓晓张卓王天玉
450000郑州,郑州大学附属郑州中心医院神经介入科(王圣杰、刘俊中、尹帅领、郭广涛、毛立武、周游、孟飞龙、谢晓晓、张卓、王天玉)
Author(s):
WANG Sheng-jie LIU Jun-zhong YIN Shuai-ling GOU Guang-tao MAO Li-wu ZHOU You MENG Fei-long XIE Xiao-xiao ZHANG Zhuo WANG Tian-yu
Department of Neurointervention, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
关键词:
颅内动脉粥样硬化性狭窄支架置入术Enterprise支架支架内再狭窄危险因素
Keywords:
Intracranial atherosclerosis Stenting Enterprise stent In-stent restenosis Risk factor
分类号:
R743;R815.2
DOI:
10.13798/j.issn.1009-153X.2023.01.002
文献标志码:
A
摘要:
目的 探讨颅内动脉粥样硬化性狭窄(ICAS)Enterprise支架置入术后支架内再狭窄(ISR)的危险因素。方法 回顾性分析2019年1月至2021年12月接受Enterprise支架置入术治疗的178例ICAS的临床资料。结果 术后随访3~14个月,平均8.1个月,178例DSA随访显示,29例发生ISR,发生率为16.29%。多因素logistic回归分析显示,Mori分型、斑块钙化程度、残余狭窄、病变部位、mTICI分级、术中夹层是ISR的独立危险因素(P<0.05)。结论 ICAS病人Enterprise支架置入术后发生ISR的危险因素众多,临床上,应充分评估ISR的危险因素并且积极采取措施控制风险因素,从而降低ISR的发生率。
Abstract:
Objective To explore the risk factors for in-stent restenosis (ISR) in patients with symptomatic intracranial atherosclerotic stenosis (ICAS) after Enterprise stenting. Methods The clinical data of 178 patients with symptomatic ICAS who received Enterprise stenting from January 2019 to December 2021 were analyzed retrospectively. The postoperative follow-up ranged from 3 months to 14 months, with an average of 8.1 months. Results ISR occurred in 29 patients, with an incidence of 16.29%. Multivariate logistic regression analysis showed that Mori classification, degree of plaque calcification, residual stenosis, lesion site, mTICI grade, and intraoperative dissection were independent risk factors for ISR (P<0.05). Conclusions There are many risk factors for ISR in ICAS patients after Enterprise stenting. In the clinic, the risk factors of ISR should be fully evaluated and measures should be taken to control the risk factors, to reduce the incidence of ISR.

参考文献/References:

[1]Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study [J]. Stroke, 2014, 45(3): 663-669.
[2]Park SC, Cho SH, Kim MK, et al. Long-term outcome of angioplasty using a wingspan stent, post-stent balloon dilation and aggressive restenosis management for intracranial arterial stenosis [J]. Clin Neuroradiol, 2020, 30(1): 159-169.
[3]陈 虎,邓剑平,于 嘉,等. 急性颅内大动脉粥样硬化性狭窄继发闭塞与单纯栓塞性闭塞的血管内治疗分析[J]. 中国临床神经外科杂志,2020,25:70-72.
[4]Levy EI, Turk AS, Albuquerque FC, et al. Wingspan instent restenosis and thrombosis: incidence, clinical presentation, and management [J]. Neurosurgery, 2007, 61(3): 644-650.
[5]Vajda Z, Schmid E, Guthe T, et al. The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent [J]. Neurosurgery, 2012, 70(1): 91-101.
[6]Feng Z, Duan G, Zhang P, et al. Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients [J]. BMC Neurol, 2015, 15: 187.
[7]刘 恋,马 宁,莫大鹏,等. Enterprise支架治疗复杂症状性颅内动脉粥样硬化性狭窄[J]. 中国卒中杂志,2017,12:592-597.
[8]Gao B, Safain MG, Malek AM. Enterprise stenting for intracranial aneurysm treatment induces dynamic and reversible age-dependent stenosis in cerebral arteries [J]. J Neurointerv Surg, 2015, 7(4): 297-302.
[9]Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans [J]. Circulation, 2002, 105(25): 2974-2980.
[10]Lee KY, Chen DY, Hsu HL, et al. Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise: Evaluation of clinical and vascular outcome [J]. Interv Neuroradiol, 2016, 22(2): 187-195.
[11]Wang ZL, Gao BL, Li TX, et al. Symptomatic intracranial vertebral artery atherosclerotic stenosis (≥70%) with concurrent contralateral vertebral atherosclerotic diseases in 88 patients treated with the intracranial stenting [J]. Eur J Radiol, 2015, 84(9): 1801-1804.
[12]Zhang K, Li TX, Wang ZL, et al. Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases [J]. Sci Rep, 2021, 11(1): 10479.
[13]Zhu Y, Xian X, Wang Z, et al. Research progress on the relationship between atherosclerosis and inflammation [J]. Biomolecules, 2018, 8(3): 80.
[14]Valdivia y Alvarado M, Ebrahimi N, Benndorf G. Study of conformability of the new leo plus stent to a curved vascular model using flat-panel detector computed tomography (DynaCT) [J]. Neurosurgery, 2009, 64(3 Suppl): ons130-134.
[15]Kang K, Zhang Y, Shuai J, et al. Balloon-mounted stenting for ICAS in a multicenter registry study in China: a comparison with the WEAVE/WOVEN trial [J]. J Neurointerv Surg, 2021, 13(10): 894-899.
[16]Peng G, Zhang Y, Miao Z. Incidence and risk factors of instent restenosis for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis [J]. AJNR Am J Neuroradiol, 2020, 41(8): 1447-1452.

相似文献/References:

[1]唐 铸 桂 铮 李延良 赵建伍 余天垒 张鹏飞 赵立文 于耀宇.药物PAS与支架置入术治疗症状性颈动脉重度狭窄的近期疗效对比分析[J].中国临床神经外科杂志,2015,(12):727.[doi:10.13798/j.issn.1009-153X.2015.12.007]
 TANG Zhu,GUI Zheng,LI Yan-liang,et al.Comparison of clinical effect of intensive therapy with PAS on severe symptomatic carotid artery stenosis with that of carotid artery stenting[J].,2015,(01):727.[doi:10.13798/j.issn.1009-153X.2015.12.007]
[2]魏 恒 马江红 张 华 曹 敏 徐丽琴 曾静霞.Wingspan支架置入术治疗椎动脉狭窄的疗效观察[J].中国临床神经外科杂志,2015,(07):430.[doi:10.13798/j.issn.1009-153X.2015.07.017]
[3]张鹏飞 赵立文 汪子文 唐 铸 赵文可 何一川 杨俊丽 于耀宇.内膜斑块剥脱术与支架置入术治疗颈动脉狭窄的Meta分析[J].中国临床神经外科杂志,2016,(08):455.[doi:10.13798/j.issn.1009-153X.2016.08.003]
 ZHANG Peng-fei,ZHAO Li-wen,WANG Zi-wen,et al.Endarterectomy versus stenting for carotid artery stenosis: a meta-analysis of randomized controlled clinical trials[J].,2016,(01):455.[doi:10.13798/j.issn.1009-153X.2016.08.003]
[4]燕景锋 樊立华 任崇文 贾增强 何金超 孙 鹏.单一支架置入术治疗椎-锁骨下动脉联合狭窄[J].中国临床神经外科杂志,2017,(05):290.[doi:10.13798/j.issn.1009-153X.2017.05.002]
 YAN Jing-feng,FAN Li-hua,REN Chong-wen,et al.Outcomes of single stent technique in subclavian-vertebral artery bifurcation series stenoses[J].,2017,(01):290.[doi:10.13798/j.issn.1009-153X.2017.05.002]
[5]张 纯 冯娟娟 李 倩 郑 婷 方 艳.经颈动脉插管行弹簧圈栓塞右侧颈内动脉眼动脉段 动脉瘤+支架置入术1例的护理[J].中国临床神经外科杂志,2018,(12):819.[doi:10.13798/j.issn.1009-153X.2018.12.021]
[6]朱金钊 张建刚 杨清成 冯 光.一期支架置入补救治疗急性后循环大动脉闭塞机械取栓术失败病人的疗效[J].中国临床神经外科杂志,2019,(09):531.[doi:10.13798/j.issn.1009-153X.2019.09.006]
 ZHU Jin-zhao,ZHANG Jian-gang,YANG Qing-cheng,et al.Effect of one-stage stent implantation on the prognoses of patients with acute posterior cerebral large artery occlusive infarction after failure of mechanical thrombectomy[J].,2019,(01):531.[doi:10.13798/j.issn.1009-153X.2019.09.006]
[7]王 冰 陈 虎 李 江 邓剑平 何宜轩 赵振伟.颅内前循环wingspan支架内再狭窄的危险因素分析[J].中国临床神经外科杂志,2021,26(06):419.[doi:10.13798/j.issn.1009-153X.2021.06.005]
 WANG Bing,CHEN Hu,LI Jiang,et al.Risk factors for in-stent restenosis after wingspan stenting in patients with atherosclerotic anterior circulation stenosis[J].,2021,26(01):419.[doi:10.13798/j.issn.1009-153X.2021.06.005]
[8]屈晓东 张晟豪 马文龙等.神经内镜下囊肿-侧脑室造瘘+支架置入术治疗颅内巨大蛛网膜囊肿1例[J].中国临床神经外科杂志,2021,26(09):735.[doi:10.13798/j.issn.1009-153X.2021.09.029]
[9]杨松,周旭,刘敬禹,等.国产药物洗脱支架(Bridge)在颅内前循环血管狭窄中的应用[J].中国临床神经外科杂志,2023,28(08):497.[doi:10.13798/j.issn.1009-153X.2023.08.006]
 YANG Song,ZHOU Xu,LIU Jing-yu,et al.Application of domestic rapamycin eluting stents (Bridgein) in patients with anterior circulation intra-cranial stenosis[J].,2023,28(01):497.[doi:10.13798/j.issn.1009-153X.2023.08.006]

备注/Memo

备注/Memo:
(2022-10-31收稿,2022-12-25修回)
通讯作者:王天玉,E-mail:xlhywangtianyu@163.com
更新日期/Last Update: 2022-02-28